Mave Health Raises $2.1M to Expand tDCS Headset to US and India

Key Takeaways

1. Bengaluru and San Francisco-based Mave Health secured $2.1 million (~INR 18 crore) in a seed round led by Blume Ventures, bringing its total funding to nearly $3 million including a $750K pre-seed in 2023
2. The funds will be deployed to launch a tDCS wearable headset priced at $495 (INR 29,500 in India) in the US and Indian markets, with shipping starting April 2026
3. Mave completed a 500-person beta, with 80% of users reporting over 60% productivity gains and 75% reporting reduced stress within four weeks
4. The company operates in a global portable tDCS market valued at $412.7 million in 2025, projected to grow at an 11.4% CAGR to reach $1.09 billion by 2034

Quick Recap

In a significant move for India’s deeptech and mental wellness ecosystem, Bengaluru-San Francisco neurotechnology startup Mave Health has officially closed a $2.1 million seed funding round led by Blume Ventures, as announced via Business Wire on March 17, 2026.

Participation came from Inuka Capital, Stanford Angels, All In Capital, Aureolis Ventures, the founders of Groww, and angel investors including Dhaval Shroff and Raymond Russell. The capital will directly fund the commercial launch of its flagship tDCS wearable headset across India and the United States, along with scaling up manufacturing.

The Technology Behind the Headband

Founded in 2023 by Dhawal Jain, Jai Sharma, and Aman Kumar, Mave Health builds non-invasive wearable headsets that use transcranial direct current stimulation (tDCS) to deliver low-intensity electrical signals to the brain’s prefrontal cortex, the region governing attention, emotional regulation, and stress response. The tDCS technique has been researched for over 25 years, with more than 10,000 published studies globally, lending it a well-established safety profile that makes it uniquely suited for unsupervised, at-home use.

The Mave headset weighs approximately 100 grams, requires no learning curve, and is designed for 20-minute daily sessions that users can do while working, reading, or meditating. A companion mobile app lets users log sessions, personalize protocols, and track progress, with the company explicitly committing to a privacy-first model that collects no raw brain data. The device runs up to one month on a single charge under regular use, a practical specification that matters greatly for daily habit formation.

The $2.1M seed raise follows a $750K pre-seed round in 2023 and a $720K bridge from All In Capital and iSeed in April 2024, building a total capitalization of nearly $3 million at this stage. CEO Dhawal Jain summarized the product vision bluntly at launch: “Most of us only think about mental health when something goes wrong,” pointing to a preventative rather than reactive market positioning.

Why This Matters Right Now?

Mave Health’s fundraise lands at a uniquely favorable regulatory and market moment for tDCS devices. In January 2026, just weeks before Mave’s announcement, Sweden-based Flow Neuroscience received US FDA 510(k) approval for its tDCS headset to treat major depressive disorder, marking the first-ever regulatory greenlight for an at-home brain stimulation device for depression in the United States. That precedent normalizes the entire consumer tDCS category in the eyes of regulators, investors, and buyers, and gives Mave Health a regulatory tailwind it could not have had two years ago.

On the macro side, the global portable tDCS devices market stood at $412.7 million in 2025 and is forecast to nearly triple to $1.09 billion by 2034 at an 11.4% CAGR, with the wearable devices segment commanding a 57.3% share of that revenue pool. North America held 38.4% of global revenue in 2025, making the US market a natural first stop for any well-capitalized tDCS startup. India, where Blume Ventures has long tracked the mental health care market as a roughly $3 billion opportunity with severe supply constraints in qualified mental health professionals, represents the second natural frontier.

Competitive Landscape

Mave Health is not entering an empty field. Flow Neuroscience and Thync (now known as Thync/Halo) are the two most directly comparable consumer-facing wearable neurostimulation companies targeting the same tDCS user population.

Flow Neuroscience leads on regulatory credibility and clinical evidence, making it the go-to option for healthcare providers treating diagnosed depression. Mave Health, however, wins on price accessibility, subscription-free structure, and a dual-market footprint that directly captures the enormous, underserved Indian wellness consumer base. In that preventive, everyday-use segment, neither Flow nor Thync has made a meaningful play.

Bayelsa Watch’s Takeaway

I will be honest: when I first saw the seed amount, $2.1 million felt modest for a hardware startup trying to ship in two geographically complex markets simultaneously. But the more I looked at the structure of this deal, the more I think this is genuinely one of the more interesting seed rounds in India’s deeptech health space this quarter. In my experience covering wearable health funding, companies that try to sell a physical neurotech device straight to consumers tend to burn fast and pivot hard.

Mave Health has done two things smart founders rarely do at seed: they ran a 500-person paid beta before spending investor money on marketing, and they priced the device at $495 with zero subscription fees, which removes a recurring objection that kills user adoption for most consumer wellness hardware.

The FDA’s January 2026 clearance of Flow Neuroscience’s device for depression is, in my view, a quiet but powerful unlock for this entire category. It signals to the market that tDCS is real, safe, and regulatory-ready. I think Mave is well-positioned to ride that tailwind, especially for the Indian market where mental health hardware of this kind has essentially no direct competition at this price point.